Justification Of Empiric Methodology to Determine Dexmedetomidine Dose for the TREX Study.

ABSTRACT:

Introduction

Dexmedetomidine is the sedative agent administered in combination with remifentanil and low dose of sevoflurane in the interventional arm of the ongoing TREX trial (Trial Remifentanil DExmedetomidine). The TREX pilot study (published in Paediatr Anaesth 2019;29:59-67) established infusion rates higher than those initially proposed. This could be attributed to an inappropriate target concentration for sedation or incorrect initial pharmacokinetic parameter estimates.

Methods

The TREX study is a Phase III, randomized, active controlled, parallel group, blinded evaluator, multicentre, superiority trial comparing neurological outcome after standard sevoflurane anaesthesia with dexmedetomidine/remifentanil and low dose sevoflurane anaesthesia in children aged less th

SUBMITTER: Disma N 

PROVIDER: S-EPMC10107467 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature